Agarikon Index Sets New Standard for Psychedelic Medicine Data

Comprehensive, Auditable Index Launches for Psychedelic Medicine

Agarikon has launched a rigorously screened, multi-layered index that consolidates psychedelic medicine data across clinics, trials, researchers, legislation, and industry actors in dozens of countries. This new resource, detailed in its October 2026 publication and available at agarikon-index.com/data, addresses the field’s chronic fragmentation by linking disparate datasets with explicit source citations and legal status for each entry. Agarikon’s approach enables researchers, clinicians, policymakers, and investors to map the landscape, assess legal risk, and identify access points with a level of transparency and auditability previously unavailable in psychedelic medicine.

How Agarikon Works: Screening, Provenance, and Data Integrity

Agarikon’s methodology relies on rigorous screening rather than automated scraping, setting it apart from prior directories and industry maps. Each data point—whether a clinic, trial, researcher, or legislative bill—is subjected to a three-stage process: relevance classification at ingestion, validation at merge, and quarantine with a written exclusion reason before publication. Notably, Agarikon publishes an explicit exclusion log (EXCLUSION_LOG.md and exclusion_log.csv), ensuring that every decision to include or exclude a record is auditable and transparent. This process is a methodological feature, not a footnote, and directly addresses concerns about data quality and silent omissions that have plagued previous efforts in the field.

The index covers 2,564 clinics, 282 retreats or legal-access points, 1,619 registered clinical trials, 1,660 researchers with a 9,757-publication corpus, 173 organizations (funders, suppliers, trainers, insurers, regulators), and 1,532 tracked state legislative bills. Each entry is linked to its enabling statute or regulatory basis when available, particularly for retreats and legal-access points, while clinics operating under general medical law are noted as such. Data sources include ClinicalTrials.gov, CMS Open Payments, DEA quotas, OpenAlex, PubMed, LegiScan, and aggregated public directories, with licensing and attribution requirements clearly stated per source.

Policy, Research, and Industry Implications

The consolidation and transparent provenance of Agarikon’s index have immediate implications for policy analysis, clinical research, and industry development. For policymakers, the ability to trace each clinic or access point to its enabling statute or jurisdictional authority provides a concrete foundation for legal risk assessment and regulatory planning. Researchers benefit from a unified map of clinical trials and publication networks, facilitating meta-analyses and identification of research gaps. Industry actors—including funders, insurers, and operators—can now evaluate market opportunities and compliance risks with a level of granularity and trust previously unavailable.

One non-obvious implication is Agarikon’s explicit tracking of exclusions and ambiguous records, which allows users to audit not just what is present but what has been left out—and why. This feature is especially relevant in jurisdictions with rapidly changing laws or contested legal interpretations, where silent data omissions can mislead stakeholders. By foregrounding these edges, Agarikon enables more informed decision-making and reduces the reputational and legal risks associated with relying on incomplete or unverified data.

Risks, Limitations, and Unknowns

While Agarikon sets a new benchmark for data integrity, several risks and limitations remain. The clinics dataset, for example, is a screened aggregation from public directories and state licensing feeds, not an independently verified census. Legal-status classifications are only as current as the underlying legislative or regulatory sources, which can change rapidly, especially at the state or provincial level. Furthermore, the index’s reliance on explicit, published exclusion criteria means that some edge cases—such as clinics operating in legal gray zones or under contested statutes—may be flagged but not fully resolved within the dataset.

Another challenge is the mixed licensing regime: while much of the data is public domain or permissively licensed, some legislative data (e.g., from LegiScan) requires attribution and cannot be blanket-reused. Users must navigate these licensing constraints when integrating Agarikon data into their own tools or analyses. Finally, as with any living index, the value depends on regular updates and community feedback to capture new developments and correct errors.

Looking Forward: A Living Reference for a Rapidly Evolving Field

Agarikon’s daily-rebuilt, auditable index represents a significant advance in the infrastructure supporting psychedelic medicine research, policy, and industry. As the field continues to evolve—with shifting legal frameworks, new clinical trials, and emerging access models—the need for reliable, transparent, and up-to-date data will only grow. Agarikon’s explicit documentation of both inclusions and exclusions provides a model for other fields grappling with fragmented, high-stakes data landscapes. For stakeholders, the index offers not just a snapshot but a living reference layer, supporting evidence-based decisions in a domain where the costs of error are high and the pace of change is accelerating.

How we research: This article was written and reviewed by Dr. Alex M. Carter, PhD (Neuroscience Policy), on 2026-10-02. Primary sources include the OpenAlex record and the Agarikon index documentation.